Unfortunately, mTOR inhibitors do not appear to improve PFS relative to standard chemotherapy regimens or provide OS benefit in TSC1/TSC2 mutated malignant PEComas (38, 73). This evidence concerns the gene TSC1 and neoplasm with perivascular epithelioid cell differentiation.